ReviewAntiviral research2013
Experimental therapies for yellow fever.
Review in Antiviral research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- A Review of Yellow Fever: Epidemiology, Pathogenesis, Clinical Manifestations, Treatment, Prevention, and Prognosis.Cureus · 2026Review
- Modes of action of a small molecule antiviral compound targeting yellow fever virus NS4B protein.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Yellow Fever in Non-Human Primates: A Veterinary Guide from a One Health Perspective.Veterinary sciences · 2025Review
- Intensive Therapeutic Plasma Exchange-New Approach to Treat and Rescue Patients with Severe Form of Yellow Fever.Tropical medicine and infectious disease · 2025Article
- Novel Pyrazino[1,2-Viruses · 2024Article
- Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal Activity.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus.Antiviral research · 2020Article
- Review
- Review
- Current Status of Dengue Therapeutics Research and Development.The Journal of infectious diseases · 2017Review
- Synthesis and insecticidal activity of acridone derivatives to Aedes aegypti and Culex quinquefasciatus larvae and non-target aquatic species.Scientific reports · 2017Article
- A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein.Journal of virology · 2016Article
- A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.Antiviral research · 2016Article
- Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention.Reviews in medical virology · 2015Review
- A DNA vaccine against yellow fever virus: development and evaluation.PLoS neglected tropical diseases · 2015Article
- Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.Virology · 2014Article
- BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.Antimicrobial agents and chemotherapy · 2014Article
- Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.Antiviral research · 2014Article
- Intervention strategies for emerging viruses: use of antivirals.Current opinion in virology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
A number of viruses in the family Flaviviridae are the focus of efforts to develop effective antiviral therapies. Success has been achieved with inhibitors for the treatment of hepatitis C, and there is interest in clinical trials of drugs against dengue fever. Antiviral therapies have also been evaluated in patients with Japanese encephalitis and West Nile encephalitis. However, no treatment has been developed against the prototype flavivirus, yellow fever virus (YFV). Despite the availability of the live, attenuated 17D vaccine, thousands of cases of YF continue to occur each year in Africa and South America, with a significant mortality rate. In addition, a small number of vaccinees develop severe systemic infections with the 17D virus. This paper reviews current efforts to develop antiviral therapies, either directly targeting the virus or blocking detrimental host responses to infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.